Sonum Singh, MD
Endocrinology, Diabetes & Metabolism · Springfield, PANPI 1659765873
Payments from drug & device makers
Across 224 payments — averaging $71.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$11K
- Novo Nordisk$551
- Medtronic$515
- Lilly USA, LLC$456
- Amgen$361
- Abbott$303
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$10,09863%
- Travel & lodging$8405%
- Food & beverage$4,91631%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 17 | $11,360 |
| Novo Nordisk | 27 | $551 |
| Medtronic(2 entities) | 18 | $515 |
| Lilly USA, LLC | 26 | $456 |
| Amgen(2 entities) | 13 | $361 |
| Abbott | 16 | $303 |
| Bayer | 14 | $293 |
| AbbVie | 11 | $274 |
| Xeris Pharmaceuticals, Inc. | 12 | $240 |
| Sanofi-aventis U.S. LLC | 8 | $190 |
| Boehringer Ingelheim | 8 | $174 |
| Tandem Diabetes Care, Inc. | 5 | $173 |
| Mannkind Corporation | 7 | $153 |
| BD | 5 | $109 |
| Ascensia Diabetes Care US Inc. | 4 | $94 |
| Amneal Pharmaceuticals LLC | 5 | $91 |
| AstraZeneca | 3 | $66 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Novartis | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Radius Health, Inc. | 2 | $43 |
| Intra-sana Laboratories | 2 | $37 |
| IBSA Pharma Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| Merck | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$11,092
- DEXCOM STELO GLUCOSE BIOSENSOR$11,092
- TEPEZZA$109
How this compares
$15,907 in reported general payments places this provider in the 75th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 422 | $501,624 |
| TrulicityDulaglutide | 366 | $430,862 |
| JardianceEmpagliflozin | 321 | $331,144 |
| MounjaroTirzepatide | 191 | $259,209 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $92,110 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $84,378 |
| JanuviaSitagliptin Phosphate | 82 | $73,187 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $67,890 |
| RybelsusSemaglutide | 35 | $49,565 |
| FarxigaDapagliflozin Propanediol | 48 | $49,092 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $37,346 |
| Gvoke Hypopen 2-PackGlucagon | 57 | $34,582 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 77 | $32,649 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 273 | $31,034 |
| TradjentaLinagliptin | 25 | $23,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $456 | $690,071557 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $551 | $557,211488 claims |
| Boehringer IngelheimJardiance, Tradjenta | $174 | $355,009346 claims |
| MerckJanuvia | $24 | $73,18782 claims |
| AstraZenecaFarxiga | $66 | $49,09248 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $91 | $6,908427 claims |
| AbbVieSynthroid | $274 | $4,29262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Springfield
- Jeffrey FreemanSpringfield$225K
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.